US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% AMD $633.91 ▲+0.00% NVDA $233.95 ▲+0.00% TSLA $370.59 ▲+0.00% SPCX $158.96 ▲+0.00% SNDK $1,719.99 ▲+0.00% SDEV $7.48 ▲+0.00%
FinancialContent

Articles published by Eledon Pharmaceuticals, Inc.

< Previous 1 2 Next >
News headline image
Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
News headline image
Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
News headline image
Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
News headline image
Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
News headline image
Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
News headline image
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
News headline image
Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
News headline image
Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
News headline image
Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
News headline image
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
News headline image
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
News headline image
Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
News headline image
Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
News headline image
Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
News headline image
Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
News headline image
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
News headline image
Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
News headline image
Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
News headline image
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
News headline image
Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
News headline image
Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
News headline image
Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology’s Kidney Week 2025 Annual Meeting
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
News headline image
Eledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation Conference
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
News headline image
Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
News headline image
Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
News headline image
Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
News headline image
Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
News headline image
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
News headline image
Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
News headline image
Updated Data from Eledon Pharmaceuticals’ Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025
From Eledon Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ELDN
< Previous 1 2 Next >